CXCL8 and neoplasm: Importantly, coadministration of anti-VEGF/anti-IL8 nAb's with enzalutamide from treatment day 14 resulted in a sustained attenuation of tumor oxygenation for the duration of the study (P < 0.001; Fig. 1A).